Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab plus minus Ipilimumab.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CRUCIAL
- 13 Dec 2018 Planned initiation date changed from 1 Sep 2018 to 15 Dec 2018.
- 25 Jul 2018 Planned End Date changed from 15 Feb 2022 to 15 Apr 2022.
- 25 Jul 2018 Planned primary completion date changed from 15 Feb 2022 to 15 Apr 2022.